Written in Blood

This section features research from recent issues of Blood.

  • Self-Reporting Significantly Overestimates Treatment Adherence in Pediatric Patients With Acute Lymphocytic Leukemia Wednesday, February 22nd, 2017 | March 2017, Volume 3, Issue 4

    Maintenance therapy with oral 6-mercaptopurine (6MP) for pediatric patients with acute lymphocytic leukemia (ALL) is crucial for maintaining a durable remission, and poor adherence is associated with an increased risk of relapse. Although self-reporting is a convenient and inexpensive method to monitor 6MP intake, it frequently leads to over-estimation of drug compliance, according to results […]

  • Choosing Between Strategies for Managing Fetal or Neonatal Alloimmune Thrombocytopenia Tuesday, February 14th, 2017 | March 2017, Volume 3, Issue 4

    For women diagnosed with fetal and neonatal alloimmune thrombocytopenia (FNAIT), a noninvasive strategy of weekly intravenous immunoglobulin infusion (IVIg) and corticosteroids could help prevent the development of FNAIT in subsequent pregnancies, according to the results of a systematic review published in Blood. More invasive strategies, such as serial fetal blood sampling (FBS) and intrauterine platelet […]

  • Assessing Lenalidomide Plus Rituximab for Patients With MALT Lymphoma Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    Patients with advanced mucosa-associated lymphoid tissue (MALT) lymphoma are often treated with chemotherapy-based regimens; however, because of the indolent course of the disease, researchers are investigating immunomodulatory, chemotherapy-free strategies, including the combination of lenalidomide and rituximab. In a Letter to the Editor published in Blood, Barbara Kiesewetter, MD, of the Division of Oncology at the […]

  • Where Does Clofarabine Fit in the Treatment of Patients With Acute Myeloid Leukemia? Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    Adding clofarabine – a second-generation nucleoside analogue – to a standard induction regimen reduced the risk of relapse for patients with newly diagnosed acute myeloid leukemia (AML), but did not improve survival, compared with induction therapy alone, according to results of an open-label, randomized, phase III study published in Blood. The drug did improve survival […]

  • Long-Term Analysis Identifies Encouraging Trends in Hemophilia A Care Thursday, February 2nd, 2017 | February 2017, Volume 3, Issue 3

    From 1999 to 2010, bleeding events among U.S. patients with hemophilia A have dropped dramatically, coinciding with a marked increase in the use of bleeding prophylaxis, according to an analysis of a long-term surveillance project conducted by the Centers for Disease Control and Prevention (CDC) and the United States Hemophilia Treatment Center Network (USHTCN). The […]

1 of 25
back to top